NeoGenomics, Inc. operates a network of cancer focused testing laboratories to provide genetic and molecular testing services. The company offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Hematopathology, Hereditary Cancer, Molecular Oncology and Pathology. The company operates through one segment: Laboratory Testing Segment. The Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Market Cap | 1.208 Billion | Shares Outstanding | 124.026 Million | Avg 30-day Volume | 2.484 Million |
P/E Ratio | 1442.7107 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 13.5426 | Debt to Equity | 0.2421 | EBITDA | 34.607 Million |
Price to Book Value | 8.6692 | Operating Margin | -3.1482 | Enterprise Value | 5.861 Billion |
Current Ratio | 6.132 | EPS Growth | 0 | Quick Ratio | 5.508 |
1 Yr BETA | 1.6606 | 52-week High/Low | 54.74 / 7.26 | Profit Margin | 0.9387 |
Operating Cash Flow Growth | -93.7524 | Altman Z-Score | 13.1588 | Free Cash Flow to Firm | -29.3 Million |
Earnings Report | 2022-08-04 |
Please sign in first
none
none
5.7 Thousand total shares from 1 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BONELLO WILLIAM CHIEF FINANCIAL OFFICER |
|
439,990 | 2022-04-28 | 7 |
BROWN DOUGLAS MATTHEW CHIEF STRATEGY OFFICER |
|
315,598 | 2022-04-01 | 4 |
SHOLEHVAR DAVID PRESIDENT, CLINICAL SERVICES |
|
97,236 | 2022-04-01 | 2 |
CARDOZA GEORGE PRESIDENT & COO, LAB OPS |
|
927,553 | 2022-03-01 | 4 |
GILBERT HALLEY E CHIEF LEGAL OFFICER |
|
313,350 | 2022-03-01 | 5 |
MALLON MARK CHIEF EXECUTIVE OFFICER |
|
866,844 | 2022-03-01 | 3 |
DIETER CYNTHIA J CHIEF ACCOUNTING OFFICER |
|
71,218 | 2022-03-01 | 3 |
WALLAR GINA M PRESIDENT, PHARMA SERVICES |
|
110,703 | 2022-03-01 | 5 |
MCKENZIE KATHRYN B CHIEF SUSTAINABILITY/RISK OFCR |
|
193,840 | 2022-01-11 | 3 |
BALLIET JENNIFER VP AND CHIEF CULTURE OFFICER |
|
136,052 | 2021-12-30 | 2 |
MORRIS CLIVE PRESIDENT OF INIVATA |
|
95,137 | 2021-12-30 | 3 |
|
48,829 | 2021-12-22 | 2 | |
|
0 | 2021-11-10 | 2 | |
|
50,888 | 2021-10-11 | 3 | |
|
3,440,448 | 2021-08-01 | 1 | |
|
53,278 | 2021-06-08 | 2 | |
|
106,325 | 2021-06-02 | 1 | |
|
12,941 | 2021-06-02 | 1 | |
|
20,629 | 2021-06-02 | 1 | |
|
10,800 | 2021-06-02 | 1 | |
SHOVLIN ROBERT J. PRESIDENT, CLINICAL SERVICES |
|
264,442 | 2021-05-25 | 1 |
WEISS LAWRENCE MARTIN CHIEF MEDICAL OFFICER |
|
215,224 | 2021-04-22 | 0 |
PEDULLA DENISE E GENERAL COUNSEL |
|
194,849 | 2021-03-01 | 0 |
|
1,386,451 | 2021-01-07 | 0 | |
|
66,800 | 2020-11-16 | 0 | |
VIRAG SHARON CHIEF FINANCIAL OFFICER |
|
10,944 | 2019-03-01 | 0 |
|
No longer subject to file | 2018-12-14 | 0 | |
BRODIE STEVEN G. VP - PHARMA OPERATIONS |
|
45,953 | 2018-10-22 | 0 |
ROSS STEVEN A CIO |
|
9,000 | 2018-05-10 | 0 |
BYWATER STEPHANIE K CHIEF COMPLIANCE OFFICER |
|
528 | 2018-05-01 | 0 |
|
359,474 | 2017-05-25 | 0 | |
ALBITAR MAHER CHIEF MEDICAL OFFICER |
|
60,692 | 2017-04-28 | 0 |
|
0 | 2016-02-17 | 0 | |
MACHULCZ MARK ALAN VICE PRESIDENT OF OPERATIONS |
|
0 | 2016-01-28 | 0 |
HOREL ROBERT H. VICE PRESIDENT GM PATHLOGIC |
|
51,218 | 2015-12-29 | 0 |
JONES STEVEN C EXECUTIVE VP OF FINANCE |
|
3,886,629 | 2015-11-25 | 0 |
|
1,821,650 | 2014-12-04 | 0 | |
GASPARINI ROBERT P CHIEF SCIENCE OFFICER |
|
8,439 | 2014-05-22 | 0 |
|
No longer subject to file | 2013-05-13 | 0 | |
SMITS MARK W CHIEF COMMERCIAL OFFICER |
|
6,667 | 2011-05-18 | 0 |
|
8,191,550 | 2011-05-02 | 0 | |
MILLER MARYDAWN VICE PRESIDENT OF IT |
|
0 | 2011-05-02 | 0 |
DVONCH JEROME J PRINICPAL ACCOUNTING OFFICER |
|
0 | 2011-05-02 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-02 17:46:18 -0400 | 2022-04-28 | M | 5,727 | d | 0 | direct | ||||||||||
2022-05-02 17:46:18 -0400 | 2022-04-28 | M | 5,727 | $7.52 | a | 191,548 | direct | 3.2487 | -20.7107 | 3.2487 | 2 | -20.7107 | 6 | |||
2022-04-04 19:08:00 -0400 | 2022-04-01 | A | 82,305 | a | 185,821 | direct | -4.8841 | 7.4503 | 15.6457 | 3 | -4.8841 | 2 | ||||
2022-04-04 19:07:12 -0400 | 2022-04-01 | A | 82,305 | a | 158,684 | direct | -4.8841 | 7.4503 | 15.6457 | 3 | -4.8841 | 2 | ||||
2022-04-04 19:07:32 -0400 | 2022-04-01 | A | 66,372 | a | 66,372 | direct | ||||||||||
2022-04-04 19:07:32 -0400 | 2022-04-01 | A | 30,864 | a | 30,864 | direct | -4.8841 | 7.4503 | 15.6457 | 3 | -4.8841 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
NEOGENOMICS INC NEO | 2022-05-16 22:15:03 UTC | 0.5354 | 0.2846 | 600000 |
NEOGENOMICS INC NEO | 2022-05-16 21:45:04 UTC | 0.5348 | 0.2852 | 600000 |
NEOGENOMICS INC NEO | 2022-05-16 21:15:03 UTC | 0.5348 | 0.2852 | 600000 |
NEOGENOMICS INC NEO | 2022-05-16 20:45:03 UTC | 0.5126 | 0.3074 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 20:15:03 UTC | 0.5126 | 0.3074 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 19:45:04 UTC | 0.5126 | 0.3074 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 19:15:03 UTC | 0.5126 | 0.3074 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 18:45:03 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 18:15:04 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 17:45:03 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 17:15:04 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 16:45:03 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 16:15:03 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 15:45:03 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 15:15:03 UTC | 0.57 | 0.25 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 14:45:03 UTC | 0.4839 | 0.3361 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 14:15:03 UTC | 0.4839 | 0.3361 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 13:45:04 UTC | 0.4839 | 0.3361 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 13:15:03 UTC | 0.4839 | 0.3361 | 650000 |
NEOGENOMICS INC NEO | 2022-05-16 12:45:04 UTC | 0.4839 | 0.3361 | 650000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Master Neutral Fund | NEO | -97.0 shares, $-3578.33 | 2020-09-30 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund | NEO | -5237.0 shares, $-277665.74 | 2021-01-31 | N-PORT |
Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund | NEO | -2100.0 shares, $-94857.0 | 2021-06-30 | N-PORT |
SCHWAB CAPITAL TRUST- Schwab Hedged Equity Fund | NEO | -3377.0 shares, $-155679.7 | 2021-07-31 | N-PORT |
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio | NEO | -42400.0 shares, $-2045376.0 | 2021-09-30 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | NEO | -5202.0 shares, $-177492.24 | 2021-12-31 | N-PORT |
Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund | NEO | -2998.0 shares, $-102291.76 | 2021-12-31 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | NEO | -686.0 shares, $-23406.32 | 2021-12-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | NEO | -4900.0 shares, $-167188.0 | 2021-12-31 | N-PORT |
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund | NEO | -71233.0 shares, $-1605591.82 | 2022-01-31 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | NEO | -27708.0 shares, $-624538.32 | 2022-01-31 | N-PORT |